Background Serum wnt1-induced signaling pathway protein 1 (WISP1) levels are increased with obesity, which is a common complication associated with lower extremity atherosclerotic disease (LEAD). However, to date, the relationship between elevated WISP1 levels and the incidence of lower extremity atherosclerotic disease (LEAD) in type 2 diabetes mellitus (T2DM) remains unclear. Methods 174 newly diagnosed type 2 diabetic patients were enrolled in our study. Patients were divided into two groups, LEAD group (n=100) and control group (n=74). Anthropometric parameters, blood pressure and some biochemical parameters were obtained. Body composition was detected by bioelectrical impedance analysis (BIA). Levels of serum insulin were determined by radioimmunoassay. Serum WISP1 and interleukin 6 (IL-6) levels were determined using an enzyme-linked immunosorbent assay. Results It was shown that serum WISP1 levels in diabetic patients with LEAD were higher than those without LEAD (P<0.001). Serum WISP1 levels were positively related with waist circumference (r=0.237, P=0.003), waist-hip ratio (r=0.22, P=0.006), visceral fat area (r=0.354, P<0.001), serum creatinine (r=0.192, P=0.012), interleukin 6 (r=0.182, P=0.032), c-reactive protein (r=0.681, P<0.001), triglycerides (r=0.119, P<0.001), fasting glucose (r=0.196, P=0.011), glycated hemoglobin (r=0.284, P<0.001), and HOMA-IR (r=0.285, P<0.026). Compared with the lowest tertile, the odds ratio of the middle tertile for LEAD incidence was 3.27 (95% CI, 1.24–8.64) and 4.46 (95% CI, 1.62–12.29) for the highest tertile after adjusting confounding factors. Conclusion The results suggest that increased serum WISP1 levels independently contribute to the incidence of LEAD in patients with newly diagnosed T2DM.

中文翻译：

---

血清 WISP1 水平升高与 2 型糖尿病患者下肢动脉粥样硬化疾病有关

背景 血清 wnt1 诱导的信号通路蛋白 1 (WISP1) 水平随着肥胖而增加，肥胖是与下肢动脉粥样硬化疾病 (LEAD) 相关的常见并发症。然而，迄今为止，WISP1 水平升高与 2 型糖尿病 (T2DM) 中下肢动脉粥样硬化疾病 (LEAD) 发病率之间的关系仍不清楚。方法 174 例新诊断的 2 型糖尿病患者入组研究。患者分为两组，LEAD组（n=100）和对照组（n=74）。获得了人体测量参数、血压和一些生化参数。通过生物电阻抗分析（BIA）检测身体成分。通过放射免疫测定法测定血清胰岛素水平。使用酶联免疫吸附测定法测定血清 WISP1 和白细胞介素 6 (IL-6) 水平。结果糖尿病合并LEAD患者血清WISP1水平高于未合并LEAD患者(P<0.001)。血清WISP1水平与腰围（r=0.237，P=0.003）、腰臀比（r=0.22，P=0.006）、内脏脂肪面积（r=0.354，P<0.001）、血清肌酐（r =0.192, P=0.012), 白细胞介素 6 (r=0.182, P=0.032), c-反应蛋白 (r=0.681, P<0.001), 甘油三酯 (r=0.119, P<0.001), 空腹血糖 (r= 0.196, P=0.011)、糖化血红蛋白 (r=0.284, P<0.001) 和 HOMA-IR (r=0.285, P<0.026)。与最低三分位数相比，中间三分位数的 LEAD 发病率分别为 3.27（95% CI，1.24-8.64）和 4.46（95% CI，1.62-12. 29）调整混杂因素后的最高三分位数。结论 结果表明，血清 WISP1 水平升高是新诊断 T2DM 患者 LEAD 发生率的独立因素。